Hospital admissions · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (all cause) compared with tiotropium alone (moderate certainty).
1 finding from 1 review
Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with tiotropium alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with tiotropium alone (low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Retention [ · patients with opioid dependence
Supervised dosing with a long‐acting medication showed no clear difference in retention ‐ retention at the end of treatment (number of participants) compared with unsupervised consumption (low certainty).
2 findings from 1 review
Adverse serious events (any) (number of participants) · patients with opioid dependence
It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).
1 finding from 1 review
Abstinence from unsanctioned opioid use (number of participants with urine drug screen or self‐report use) · patients with opioid dependence
1 finding from 1 review
Diversion (number of participants) · patients with opioid dependence
1 finding from 1 review
Days of unsanctioned opioid use · patients with opioid dependence
1 finding from 1 review
Mortality ‐ (number of participants) · patients with opioid dependence
1 finding from 1 review
Death from any cause · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
It is very uncertain whether long‐stored ('older') PRBC (≥ 21 days of storage) changes death from any cause compared with short‐stored (fresh) PRBC (< 21 days of storage) (very low certainty).
1 finding from 1 review
Transfusion‐related acute lung injury ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postoperative infections ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Post‐injury coagulopathy ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Multiple organ failure post‐injury ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event (Hyperkalaemia) ‐ not measured · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event (Metabolic acidosis) · patients requiring blood transfusion (children with malaria and adults with a traumatic injury)
1 finding from 1 review
Global symptoms of dyspepsia (responders) · patients with functional dyspepsia
Curcuma longa may leads to higher global symptoms of dyspepsia (responders) compared with placebo (low certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
Curcuma longa showed no clear difference in adverse events Assessed clinically compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life · patients with functional dyspepsia
1 finding from 1 review